PHYTECS

Beyond Cannabis, Many Other Plants Produce Compounds Targeting Body's Endocannabinoid System, According to New Review by Phytecs' Dr. Ethan B. Russo in *Trends in Pharmacological Sciences*

July 21, 2016 08:44 AM Pacific Daylight Time

LOS ANGELES--(BUSINESS WIRE)--Compelling evidence that many plant species beyond cannabis interact with the body's endocannabinoid system (ECS) is presented in Dr. Ethan B. Russo's new cover story for the July issue of the prestigious journal, *Trends in Pharmacological Sciences* entitled, "Beyond Cannabis: Plants and the Endocannabinoid System." Because the ECS regulates nearly every aspect of human physiology, Dr. Russo's assessment may have far-reaching implications for emerging therapies. Dr. Russo, a clinical neurologist and Medical Director of Phytecs, reviews how plants from chili peppers to turmeric to truffles, stimulate, antagonize, or modulate aspects of ECS function. In 2011, Dr. Russo popularized the concept of the cannabis entourage effectcaused by synergies among cannabis essential oils and cannabinoids such as THC and CBD. A leading expert in cannabinoid and ECS medicine, Ethan Russo served as the Senior Medical Advisor to GW Pharmaceuticals before joining Phytecs in 2015. Dr. Russo also served as the Chairman of the International Association for Cannabinoid Medicines and President of the International Cannabinoid Research Society.

"The discovery and elucidation of the endocannabinoid system led by Prof. Raphael Mechoulam has been one of the greatest research advances in medicine in the last generation," said Russo. "The role of the ECS in modulating homeostasis, or physiological balance, in human health and disease has proven to be both ubiquitous and essential. Whereas conventional wisdom has pointed to cannabis as the only option for many disorders affecting the endocannabinoid system, it is clear that cannabis is simply one tool within a much larger arsenal of approaches that includes other plants and compounds, nutritional interventions and lifestyle adjustments."

Prof. Raphael Mechoulam, Director of Global Research for Phytecs, stated, "The plant compounds noted in Dr. Russo's article produce effects beyond those associated with conventional cannabinoids, which may contribute to our understanding of the next generation of ECS medicines."

About Phytecs:

Phytecs is a biotechnology company developing interventions that address endocannabinoid system dysregulation. The Phytecs team pioneered the modern understanding of how the ECS regulates aspects of physiology including immunity, pain, inflammation, mood, emotion, learning, memory, metabolism, appetite, weight, sleep, embryo development, neuroprotection and stress response. Phytecs is currently conducting research in the United States, Hungary, Israel and Switzerland. www.phytecs.com

Contacts

Phytecs, Inc.
Gary Hiller, 310-695-1225